Reading OCUL? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track OCUL free→Reading OCUL? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track OCUL free→QuarterlyIQ Insights · OCUL
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Amendment to 2021 Stock Incentive Plan On June 10, 2026, Ocular Therapeutix, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”). At the 2026 Annual Meeting, the Company’s stockholders approved an amendment (“Amendment No. 5”) to the Company’s 2021 Stock Incentive Plan, as amended (the “2021 Stock Incentive…
Results of Operations and Financial Condition. On May 5, 2026, Ocular Therapeutix, Inc. announced its financial results for the quarter ended March 31, 2026. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with
Results of Operations and Financial Condition. On February 5, 2026, Ocular Therapeutix, Inc. announced its financial results for the quarter and year ended December 31, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective as of January 20, 2026, Donald Notman, Chief Financial Officer and Chief Operating Officer (principal financial officer and principal accounting officer) of Ocular Therapeutix, Inc. (the “Company”), is taking a temporary medical leave of absence from the Company. Accordingly, effective as of January 20, 2026 (the “Robins Effective Date”),…
Results of Operations and Financial Condition. On November 4, 2025, Ocular Therapeutix, Inc. announced its financial results for the quarter ended September 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with
Results of Operations and Financial Condition. On August 5, 2025, Ocular Therapeutix, Inc. announced its financial results for the quarter ended June 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with
Other Events. Update regarding SOL-R Clinical Trial On May 28, 2025, the Company announced that it expected enrollment in SOL-R, the Company’s ongoing repeat-dosing registrational Phase 3 clinical trial for AXPAXLI TM (also known as OTX-TKI) for the treatment of wet AMD, would close within the week. The Company completed enrollment in the SOL-R clinical trial on May 31, 2025. Based on current and projected loading and randomization failure rates observed in SOL-R to date, the Company believes…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 11, 2025, Ocular Therapeutix, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”). At the 2025 Annual Meeting, the Company’s stockholders approved (i) an amendment (“Amendment No. 4”) to the Company’s 2021 Stock Incentive Plan, as amended (the “2021 Stock Incentive Plan”) and (ii) an amendment and r…
Results of Operations and Financial Condition. On May 5, 2025, Ocular Therapeutix, Inc. announced its financial results for the quarter ended March 31, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with
Results of Operations and Financial Condition. On March 3, 2025, Ocular Therapeutix, Inc. announced its financial results for the quarter and year ended December 31, 2024. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 11, 2025 (the “Grant Date”), as part of its annual compensation review and in consultation with its independent compensation consultant, the Board of Directors (the “Board”) of Ocular Therapeutix, Inc. (the “Company”) approved a new compensation package for Pravin Dugel, M.D., the Company’s Chairman, President and Chief Executive Office…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.